Category: Peptide Q&A

What peer-reviewed publications have demonstrated SLU-PP-332’s ability to reduce amyloid-beta plaque burden in transgenic Alzheimer’s models?

What neuroimaging data (e.g., fMRI, PET) in rodent models demonstrate SLU-PP-332’s impact on cerebral blood flow and metabolic activity in regions assoc

Has SLU-PP-332 demonstrated protective effects against age-related hearing loss or retinal degeneration in animal models, and what pathways are involved

How does SLU-PP-332 compare to rapamycin in extending healthspan in C. elegans and mouse models, particularly in terms of mitochondrial function and pro

Does SLU-PP-332 cross the blood-brain barrier effectively, and what pharmacokinetic studies support its CNS bioavailability in non-human primates?

What impact does SLU-PP-332 have on neuroinflammation, particularly microglial activation and IL-1β/ TNF-α release, in the context of chronic neurodegen

What are the challenges in scaling up the synthesis of SLU-PP-332 for clinical use, and how might this affect cost and accessibility?

How does SLU-PP-332 affect insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue, and what genetic or proteomic evidence supports

How does SLU-PP-332 influence brown adipose tissue (BAT) thermogenesis and energy expenditure in cold-exposed mice?

Does SLU-PP-332 activate AMPK signaling pathways independently of changes in AMP:ATP ratio, and what evidence supports this in neuronal cells?